EGFR and breast carcinoma: Moreover, EGFR demonstrates less sensitivity to Erlotinib (overall effect = 0.16, 95% CI: −0.01 to 0.34, p = 6.52e-02) compared to the breast cancer meta-analyses where not limited to the common cell lines (overall effect = 0.26, 95% CI: 0.16 to 0.36, p = 2.47e-07) (Supplementary Figure S5).